干扰素对ET和PV的JAK2V617F基因突变负荷和IL-8的表达的影响  

Effects of interferon on JAK2V617F gene mutation load and IL-8 expression in ET and PV

作　　者：黄继贤 潘成云 廖建军 谢治军 肖捷 肖健 HUANG Ji-xian;PAN Cheng-yun;LIAO Jian-jun(Yuebei People’s Hospital Affiliated to Shantou University Medical College,Shaoguan 512025,China)

机构地区：[1]汕头大学医学院附属粤北人民医院,512025 [2]贵州医科大学附属医院,550001

出　　处：《中国实用医药》2020年第24期1-4,共4页China Practical Medicine

基　　金：广东省医学科研基金立项项目(项目编号:A2017543);韶关市科技计划项目(项目编号:2017cx/008、2019sn015)项目名称:Ph染色体阴性的MPN治疗前后细胞因子变化的研究。

摘　　要：目的探讨干扰素治疗原发性血小板增多症(ET)和真性红细胞增多症(PV)患者的效果及对JAK2V617F基因突变负荷和白细胞介素-8(IL-8)表达的影响。方法30例JAK2V617F基因突变阳性ET患者(19例)和PV患者(11例),采用干扰素α-2b治疗。观察治疗6个月后的临床指标,比较治疗前后JAK2V617F基因突变负荷和IL-8的表达水平变化情况,统计治疗后血液学疗效。结果干扰素治疗6个月后,ET+PV患者的血液学总缓解率达86.67%,其中完全血液学缓解(CHR)和部分血液学缓解(PHR)分别为70.00%和16.67%。ET和PV患者的血液学总缓解率、CHR、PHR分别为100.00%和63.64%、78.95%和54.55%、21.05%和9.09%。ET+PV、ET、PV患者干扰素治疗6个月后JAK2V617F基因突变负荷分别为(28.25±12.99)、(25.84±10.72)、(32.42±15.87)%,均低于治疗前的(44.50±23.90)、(34.48±15.02)、(67.00±19.26)%,差异均有统计学意义(P<0.05)。ET+PV、ET、PV患者干扰素治疗6个月后IL-8表达水平与治疗前比较,差异均无统计学意义(P>0.05)。结论干扰素治疗ET和PV患者6个月,能明显降低JAK2V617F基因突变负荷,使大部分患者达到血液学缓解,但并未能明显降低IL-8水平。Objective To discuss the effect of interferon on essential thrombocythemia(ET)and polycythemia vera(PV)as well as its effect on the JAK2V617F gene mutation load and expression of interleukin 8(IL-8).Methods 30 patients with JAK2V617F gene mutation positive ET(19 cases)and PV(11 cases)were treated with interferon α-2b.The clinical indicators of 6 months after treatment were observed.JAK2V617F gene mutation load and IL-8 expression level changes before and after treatment was compared,and the hematological efficacy was analyzed.Results After 6 months of interferon treatment,the total hematological remission rate of ET+PV patients was 86.67%,in which complete hematological remission(CHR)and partial hematological remission(PHR)were 70.00%and 16.67%respectively.The total remission rate,CHR and PHR of ET and PV patients were 100.00%and 63.64%,78.95%and 54.55%,21.05%and 9.09%respectively.After 6 months of interferon treatment,JAK2V617F gene mutation load of ET+PV,ET and PV patients were(28.25±12.99),(25.84±10.72)and(32.42±15.87)%respectively,which was lower than that before treatment(44.50±23.90),(34.48±15.02)and(67.00±19.26%),and the difference was statistically significant(P<0.05).After 6 months of interferon treatment,IL-8 level of ET+PV,ET and PV patients had no statistically significant difference compared with that before treatment(P>0.05).Conclusion 6 months of interferon treatment in ET and PV patients can significantly reduce the JAK2 V617F gene mutation load to hematologic response in most patients;however,it does not significantly reduce the level of IL-8.

关 键 词：干扰素 原发性血小板增多症 真性红细胞增多症 JAK2V617F基因突变 白细胞介素-8 

分 类 号：R558.3[医药卫生—血液循环系统疾病] R555.1[医药卫生—内科学]